Net profit of Mankind Pharma rose 7.50% to Rs 408.75 crore in the quarter ended December 2025 as against Rs 380.23 crore during the previous quarter ended December 2024. Sales rose 11.52% to Rs 3567.20 crore in the quarter ended December 2025 as against Rs 3198.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3567.203198.79 12 OPM %25.7725.51 - PBDT838.19675.50 24 PBT615.59488.33 26 NP408.75380.23 8 Powered by Capital Market - Live News

Mankind Pharma announced that ICRA has assigned the rating ICRA AA+; Stable / ICRA A1+ for debt facilities of the company including non-convertible debentures. The rating on commercial paper of ICRA A1+ has been withdrawn. Powered by Capital Market - Live News

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live News

Mankind Pharma has allotted 46,582 equity shares under ESOP on 26 November 2025. With this allotment, the paid up equity share capital has increased to 41,28,05,072 equity shares having face value of Re 1/- each. Powered by Capital Market - Live News

Net profit of Mankind Pharma declined 21.72% to Rs 511.51 crore in the quarter ended September 2025 as against Rs 653.47 crore during the previous quarter ended September 2024. Sales rose 20.77% to Rs 3697.16 crore in the quarter ended September 2025 as against Rs 3061.43 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales3697.163061.43 21 OPM %24.9227.67 - PBDT845.84951.72 -11 PBT624.02851.23 -27 NP511.51653.47 -22 Powered by Capital Market - Live News